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Abstract
V-erb-b2 erythroblastic leukemia viral oncogene homologue 2, known as ERBB2, is an important 
oncogene in the development of certain cancers. It can form a heterodimer with other epidermal 
growth factor receptor family members and activate kinase-mediated downstream signaling 
pathways. ERBB2 gene is located on chromosome 17 and is amplified in a subset of cancers, such 
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as breast, gastric, and colon cancer. Of particular interest to the Chromosome-Centric Human 
Proteome Project (C-HPP) initiative is the amplification mechanism that typically results in 
overexpression of a set of genes adjacent to ERBB2, which provides evidence of a linkage 
between gene location and expression. In this report we studied patient samples from ERBB2-
positive together with adjacent control nontumor tissues. In addition, non-ERBB2-expressing 
patient samples were selected as comparison to study the effect of expression of this oncogene. We 
detected 196 proteins in ERBB2-positive patient tumor samples that had minimal overlap (29 
proteins) with the non-ERBB2 tumor samples. Interaction and pathway analysis identified 
extracellular signal regulated kinase (ERK) cascade and actin polymerization and actinmyosin 
assembly contraction as pathways of importance in ERBB2+ and ERBB2− gastric cancer samples, 
respectively. The raw data files are deposited at ProteomeXchange (identifier: PXD002674) as 
well as GPMDB.
Graphical Abstract
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INTRODUCTION
Gastric cancers can be divided into intestinal type, diffuse type, and mixed type cancers 
according to the Lauren classification.1 Carcinogenesis mechanisms as well as the stromal 
compositions are significantly different for the two types of gastric cancer.1,2 In this study all 
of the cases are intestinal-type (GI cancer). The epidermal growth factor receptor (EGFR) 
superfamily of tyrosine kinase receptors,3 of which ERBB2 is a member, is one of the 
important growth factor receptor systems that are commonly overexpressed in human 
tumors.4 ERBB2 has been well studied in invasive breast cancer and predominantly used as 
biomarker for diagnosis and therapy.5 The ERBB2 amplicon has also been shown to be 
significant in cancer studies, in particular, breast cancer.5d,6 Furthermore, a subset of gastric 
cancer patients contain ERBB2 (Her-2) positive tumors and a monoclonal antibody directed 
against ERBB2 (Herceptin) is used as a treatment modality.7,8
In this study, we describe the proteomic analysis of two gastric cancer clinical sample sets, 
ERBB2-positive (ERBB2+) and the non-ERBB2-expressing (ERBB2−) tumor and matching 
control samples. Tissue samples were selected by immunohistochemistry staining (IHC 
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staining) as well as fluorescence in situ hybridization (FISH) with analysis of anti-ERBB2 
reactivity.9 Two levels of comparison are employed in our proteomic study. One comparison 
is between tumor tissue and its control sample in an individual patient, and the other is the 
comparison between ERBB2-positive and non-ERBB2-expressing samples collected from 
different patients. We also examined transcriptomic data from the two ERBB2-expressing 
gastric cancer cell lines, SNU16 and KATOIII.7,10 We will report on the results and insights 
obtained by these proteomic and transcriptomic analysis.
EXPERIMENTAL SECTION
Reagents and Materials
Trypsin (sequencing grade) was purchased from Promega (Madison, WI). Guanidine 
hydrochloride, formic acid (FA), ammonium bicarbonate, dithiothreitol (DTT), 
iodoacetamide (IAA), tris, urea, thiourea, and CHAPS were purchased from Sigma-Aldrich 
(St. Louis, MO). Protease inhibitor cocktail tablets were purchased from Roche 
(Indianapolis, IN). LC–MS grade water was purchased from J. T. Baker (Philipsburg, NJ). 
Acetonitrile with HPLC grade was purchased from Thermo Fisher Scientific (Fairlawn, NJ). 
Novex sharp unstained protein standard, RPMI 1640 media and NuPAGE 4–12% Bis-Tris 
gels were purchased from Invitrogen (Carlsbad, CA).
Selection of Patient Samples
The patient samples were selected by Dr. Hyunki Kim from Yonsei University College of 
Medicine (all patient samples were obtained in Korea) based on results from 
immunohistochemistry staining (IHC staining) as well as FISH (fluorescence in situ 
hybridization). Supplemental Table S-1a describes the selection criteria in IHC staining. The 
ERBB2+ patient samples in this paper all have positive results in immunohistochemistry 
test, which has criteria of positive (3+) as “strong complete, basolateral, or lateral 
membranous reactivity in 10% of the tumor cells”.11 The definition of fluorescence in situ 
hybridization positivity is a “HER2: chromosome 17 ratio of >2.0”. In brief, the positivity 
criteria was described as following “20 cohesive tumor cells showing highest gene count”, 
with “amplification >2.0” (“the ratio between the number of copies of the HER2 gene and 
the number of copies of chromosome 17 within the nucleus counted in at least 20 cancer 
cells were applied”).11 The criteria and definition cites the paper “HER2 Testing in Gastric 
Cancer: A Practical Approach” published in Modern Pathology in 2012. This paper 
describes the details of gastric cancer sample selection criteria, which are the same criteria 
applied to sample selection in Korea.11
Therefore, a total of 150 samples were examined and eight samples were selected as 
ERBB2+ sample sets and nine were selected as ERBB2− sample sets. The eight ERBB2+ 
patient samples all have positive results in FISH and 3+ in IHC staining. (See Supplemental 
Figure S-1b.) On the contrary, nine ERBB2− patient samples were selected (see 
Supplemental Figure S-1c): Seven samples were selected based on their negative results 
from IHC staining. There are two samples that have positive results in IHC staining. They 
were retested by FISH, and both of them show negative results in FISH. These two samples 
were classified as ERBB2−. Upon selection, these tumor tissues and the adjacent tissues 
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were used for further analysis. (Control tissues are healthy tissues surrounding cancer 
tissues.)
Protein Extraction, Separation, Fractionation, and In-Gel Digestion
Proteins were extracted from each tumor and control tissue samples by the following steps. 
Each tissue sample (~50 mg) was lysed in 250 μL of lysis buffer (30 mM Tris, 7 M urea, 2 
M thiourea, 65 mM DTT, 4% CHAPS, pH 8.8), containing protease inhibitor, followed by 
ultrasonication at 15 s intervals, 7 to 1- times, with 15 s pause between each treatment. 
Sections of the tissue sample, which were not readily lysed at the conclusion of the 
sonication process, were discarded. Each sample was then centrifuged at 14 000 rpm for 30 
min at 4 °C, and supernatants, containing the extracted proteins, were carefully recovered.
The extracted proteins were separated by SDS-PAGE for proteomic analysis. Each gel lane 
was loaded with 40 μg proteins for the control or the tumor sample. Each gel lane was sliced 
into five equal fractions. Fractions were reduced by 10 mM DTT in 0.1 M ammonium 
bicarbonate with 30 min incubation at 56 °C, followed by 1 h of incubation with 55 mM 
IAA in the dark at room temperature for alkylation. For digestion by trypsin, digestion buffer 
was prepared as 12.5 ng/μL trypsin in 50 mM ammonium bicarbonate. Gel slices were 
incubated in the digestion buffer containing trypsin at 4 °C for 35 min, followed by 
incubation in the buffer without trypsin, at 37 °C for 14 h prior to extraction. Peptides were 
extracted from the gel slices by 25 mM ammonium bicarbonate and acetonitrile, followed by 
further extraction with 5% formic acid (37 °C, 5 min vortex), and supernatants were 
collected and pooled together. The digested peptide solution was concentrated into pellets 
for storage. The pellets were reconstituted into 10 μL of 0.1% formic acid (in water) prior to 
LC–MS/MS analysis. Therefore, for each control and each tumor tissue sample, five 
fractions were analyzed by LC–MS/MS analysis.
LC-MS Analysis by LTQ-Orbitrap
The analysis was conducted by Ultimate 3000 nano-LC (Dionex, Mountain View, CA) 
coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, San Jose, 
CA). A self-packed C18 column (Magic, 200 Å pore, 5 μm particle size, 18 cm length, 75 
μm i.d.) was used. A nanospray ion source (New Objective, Woburn, MA) was used to 
couple the column online to the mass spectrometer. The reconstituted 10 μL peptide solution 
(5 fractions per sample) was used for LC–MS/MS analysis. Five out of total 10 μL was 
injected for each single run. The gradient mobile phase A was 0.1% formic acid in water, 
and mobile phase B was 0.1% formic acid in acetonitrile. The gradient was from 2% mobile 
phase B for sample loading. At 2 min, mobile phase B increases to 5%. Then, a linear 
gradient of B solvent was applied from 5 to 50% from 5 to 85 min. Then, in the next min, 
mobile phase B was changed from 50 to 90%, followed by an isocratic gradient of B at 90% 
for 5 min. Then, the organic phase (mobile phase B) decreased back to 2% in 1 min and was 
maintained for another 1 min. The flow rate was maintained at 200 nL/min.
Data were obtained from LTQ-Orbitrap for LC–MS/MS analysis. The mass spectrometer 
was operated in data-dependent mode. Precursor ion with mass window of 400–2000 m/z 
was applied in full-scan MS, with mass resolution of 30 000 at m/z 400. 2+ and 3+ were 
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selected as the most abundant charge states. 1+ and higher charge state (4+ or higher) are 
also included. The full scan was followed by eight sequential LTQ (linear ion trap)-MS2 
scans as MS/MS (MS2), fragmented by CID (collision induced dissociation) with 35% 
normalized collision energy.
Protein Identification
Peptide sequences were identified using Thermo Proteome Discoverer 1.from a human 
database SP.human.56.5 (Swiss-Prot, Release 56.5 of Nov 2008 contained 402 482 entries). 
The searching process helps to assign most probable sequences for peptides according to the 
fragmentation spectra using the Sequest algorithm. The spectra generated from CID-MS2 
were searched against the theoretical fragmentations of the proteins under studies. The 
search criteria are as follows: full trypsin specificity and up to two internal missed cleavages. 
Precursor mass tolerance was set as 20 ppm, and fragment mass tolerance was set as 0.8 Da 
as initial filter of enzymatic peptides. Dynamic modifications were deamidation of 
asparagine, and static modification was carbamidomethylation for cysteine. False discovery 
rate (FDR) as 0.01 was applied.12 Proteins with spectral counts of or more are major targets 
in the analysis. Experiments for proteomics were done once due to limited access to patient 
tissues.
The raw data files are deposited at ProteomeXchange13 (identifier: PXD002674) at 
www.proteomexchange.org. The data files have also loaded onto GPMDB14 (Global 
Proteome Machine Database) and can be located by searching the title of this paper 
“Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues” at http://
gpmdb.thegpm.org/thegpm-cgi/dblist_gpmnotes.pl.
Cell Line Growth Conditions and RNA-Seq Measurement
Gastric Cancer cell lines SNU16 and KATOIII were grown in RPMI 1640 medium: 
37 °C/5% CO2 containing hydrocortisone (1 mg/mL), insulin (24 U/L), and α-thioglycerol 
(10−6 M) with 10% FCS.
RNA-Seq, or RNA sequencing, has recently been applied for transcriptomic analysis.15 
RNA-Seq data were contributed by collaborators in triplicates. Nanodrop 2000 
spectrophotometer was used to determine the RNA concentration.15 Illumina HiSeq 2000 
equipment was used to sequence lanes of samples, and the RNA-Seq (strand-specific) library 
was prepared as well to gather transcript data. RNA-Seq data are stored in Short Read 
Archive: SRS366582, SRS366583, SRS366584, SRS366609, SRS366610, and SRS366611. 
Illumina TruSeq standard procedures were followed. The library of strandspecific RNA-Seq 
was prepared from total RNA. The sequencing was performed as paired-end RNA-
sequencing. The sequences obtained from Illumina HiSeq2000 were aligned with human 
genome (hg19) using Tophat, which is embedded with Bowtie and transcribed into gene 
transcripts (NCBI build 37.2) using Cuffinks.15 The RPKM (reads per kilobase per million 
mapped reads; a measurement of gene expression represented by absolute abundance) values 
were also calculated based on the assembly.
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RESULTS
Clinical Sample Selection
In this study we examined the proteomics of gastric cancer patients that express significant 
levels of ERBB2, a critical biomarker for gastric cancer, as well as a control group that also 
had gastric cancer but did not express the oncogene.16 Studies using immunohistochemistry 
and in situ hybridization have shown that ERBB2 is overexpressed in ~7–34% gastric 
cancers.16,17 The proportion of tumor type for ERBB2 positivity is as follows: ~30% of 
intestinal type gastric cancer, ~15% of mixed type, and ~5% of diffuse type.11 In our study, 
all patient samples analyzed are of intestinal type. A total of 150 samples were examined by 
immunohistochemistry and FISH, and eight ERBB2-positive samples and their adjacent 
nontumor tissues were selected for this study. The selection criteria from 
immunohistochemistry are listed in Supplemental Table S-1a. Additionally, another set of 
gastric cancer samples and controls was collected in the same manner but were selected as 
non-ERBB2-expressing. In Supplementary Table S-1b,c, some of the clinical parameters of 
the sample selection are listed.
Proteomics Analysis of Gastric Cancer Patient Samples
After extraction of the selected tissue sample, the protein extracts were separated by 1D 
SDS-PAGE. Supplementary Figure S-1 shows an example of a SDS-PAGE separation of 
extracted proteins from one sample of gastric cancer tumor and its control. After gel 
analysis, each gel lane was cut into five bands and the extracted proteins were digested with 
trypsin and then analyzed by LC–MS/MS. Here we used high protein confidence and high 
peptide rank and with a false discovery rate (FDR) of <1% for protein identification.
The eight gastric cancer samples with overexpression of ERBB2, together with the matching 
controls, were analyzed separately in a consecutive series of analysis. In a similar manner, 
nine non-ERBB2 expressing (ERBB2 negative) plus control samples were analyzed as a 
second sample set. ERBB2 was identified with seven unique peptides in ERBB2-positive 
gastric cancer tumor samples (total of 32 spectral counts in all eight tumor samples) but 
absent in the adjacent normal tissue samples. (See Supplementary Figure S-2a for examples 
of the MS and MS/MS identifications of both ERBB2 and EGFR.) An assessment of the 
quality of the peptides observed for ERBB2 was obtained by a comparison with the ranking 
of the corresponding peptides in GPMDB. (See Supplementary Table S-2b.)18 The data in 
GPMDB are an aggregate of observations from a large number of laboratories and sample 
types, so the frequency of observations is not an exact match for our study, but all of the 
peptides that we observed were common to many other studies.
Strategy for ERBB2-Driven Gastric Cancer Analysis
The strategy used for analysis of gastric cancer is shown in Figure 1. In-depth analysis of 
gastric cancer patient tissue samples provided around 3000 protein IDs, which gives a 
measure of the depth of protein identification. Among the identified proteins, based on the 
sensitivity of this analytical protocol, 196 and 159 are tumor unique proteins in the ERBB2-
positive (ERBB2+) and ERBB2-negative (ERBB2−) sets, respectively. Tumor unique 
proteins are identified as those below the detection limit of our LC–MS analysis in matching 
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control tissue samples. As has been used by other investigators,6b,15,19 we hypothesized that 
tumor unique proteins that are known to be interactors with known oncogenes are more 
likely to be of disease significance. We will discuss in the next section the selection of a 
panel of 21 driver oncogenes and identification of 48 interactors from the set of 196 
ERBB2+ tumor unique proteins.
Combination of Proteomic Analysis with Transcriptomics
To support the proteomic study we measured the transcriptome of two gastric cell lines by 
RNA-Seq, as described by Snyder et al.20 The analysis corresponded to deep reads with ~11 
000 transcripts measured in each analysis. While the proteomic studies were of lesser depth 
(~3000 proteins identified), we and others have shown that proteomics can aid the 
identification of significant pathways and expression events.6b,8,15,21
As part of the C-HPP initiative we have been exploring the relationship between a proteomic 
observation and the corresponding gene location on a given chromosome.22 It has been 
noted that cancer as an evolutionary process exploits regions of high transcription activity.22 
As a broad measure of the level of protein expression for a genomic region, Figure 2 shows 
the number of proteins identified in the ERBB2-positive proteomic study as a percentage of 
the number of protein coding genes on the respective chromosome. The observation of a 
higher percentage observed in a given chromosome can result from a combination of factors 
such as the constitutive expression of housekeeping proteins as well as gene amplification 
related to oncogene expression. An example of the high-level expression of housekeeping 
proteins in our study was the observation of high levels of the following chromosome 12 
gene products: GAPDH, TUB1A, TUB1B, TUB1C, and KRT1. Conversely the higher % 
observed on chromosome 17 could be related to gene amplification related to the expression 
of the oncogene ERBB2. This amplification is illustrated by a copy number variation (CNV) 
analysis of a gastric tumor sample expressing a high level of ERBB2 and indeed does show 
an extensive amplification of the genomic region containing this oncogene. (See Figure 3.)
Discussion
Comparison of Tumor and Control Samples—Proteomic analysis identified around 
3000 proteins in the gastric cancer tissue samples. These identifications are listed, together 
with their chromosome location (base start and end), band location, spectral counts, as well 
as the RNA-Seq values for two gastric cancer cell lines (SNU16 and KATOIII) in the 
Supplementary Table S-3a, and the corresponding data set for the ERBB2− sample analysis 
is listed in Supplementary Table S-3b. We concentrated on proteins that were detected 
exclusively in the tumor samples (absent in the control samples). To reduce individual 
variability caused by factors such as tumor grade, tumor location, as well as other patient 
variables, the observations for the ERBB2-positive and ERBB2-negative groups and the 
control samples were pooled separately (total of four pooled data sets). The numbers of 
proteins unique to ERBB2-positive and -negative tumors compared with their controls were 
196 and 159, respectively, with only 29 proteins common between these two data sets 
(Figure 4). This result indicates that the classification of tumor samples into ERBB2+ and 
ERBB2− allowed the selection of distinct disease phenotypes.
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As an example of this large data set, the 20 most abundant tumor unique proteins (out of the 
196 proteins) are listed in Table 1, with different colors to denote the number of proteins 
which have general cancer associations (12 out of 20), including ERBB2, some are 
specifically gastric cancer associated (4 out of 20), as well as some structural proteins (4 out 
of 20).4a,b
ERBB2 Amplicon—This study has illustrated the effective integration of transcriptomic 
and proteomic data, one of the C-HPP strategies recently outlined.5d Another aspect of this 
informative approach is that the proteomic researcher can better understand the genomic 
context of their observations. Thus, in addition to the study of specific ERBB2 pathways as 
potential cancer markers, we also investigated the ERBB2 amplicon that had been 
previously identified in breast cancer.6a,24 In this context, an amplicon is defined as a set of 
colocated genes that are also coamplified with the oncogene. In Figure 5, we plot the protein 
identifications in the gastric cancer study for three bands known to be part of the ERBB2 
amplicon on chromosome 17, namely, q12, q21.2, and q21.3.5d To illustrate the genomic 
context of the proteomic identifications, we show the number of bases in the interval 
between each protein-coding gene observed in our proteomic study as well as RNA-Seq 
values for the cell lines. As shown in this Figure, three proximal genes, PPP1R1B, ERBB2, 
and GRB7, are strongly associated with the gastric cancer tumor samples.25
The results are consistent with a comparable study by our group in breast cancer.6b It has 
been reported5d that “The amplicon can be of different size in patients and may be larger in 
breast than other cancers. Such speculations require a better set of markers to define the size 
of the amplicon and the supplementation of genomic with proteomic data.” As an example 
of the additional information shown in Figure 5: PP1R1B was separated from ERBB2 by 4 
genes whose proteins products were not observed in the proteomic study (51.5 kB) but 2 of 
which had RNA-Seq values greater than 1. The reason for the lack of detection of these two 
genes is not known but the RNA-Seq information can be used to guide future targeted 
studies.
A proteomics signal was observed for the genes PPP1R1B, ERBB2, GRB7, GSDMB, 
PSMD3, and TOP2A in the ERBB2+ but not ERBB2− sample sets. (See Figure 5.) We 
propose that this set of proteomic measurements could be used to define the extent of the 
ERBB2 amplicon in these patients. and further studies will be required to establish the 
generality of these observations. The comparison between ERBB2+ and ERBB2− sample 
sets shows the differences in protein expression of the ERBB2 amplicon. Other studies have 
shown that a group of genes is coamplified with the oncogene ERBB2 by such mechanism 
as chromosomal breakage and resynthesis.26 Similar amplicons, which have also been 
reported for EGFR and Myc (c-Myc), represent a mixture of passenger genes as well as 
genes that are functionally linked to the oncogenic process.27 In the case of ERBB2 the 
adjacent genes GRB7 (nuclear transport of ERBB2),4b PGAP(synthesis of the lipid raft 
involved in the heterodimerization of ERBB2 and EGFR),28 and TOP2A (DNA replication 
and synthesis)29 have been functionally linked, and PPP1R1B has been identified as part of 
an oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon.30 
These observations are consistent with the suggestion that in certain cases genes with related 
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functions may be located in the same genomic region and exhibit coordinated expression in 
specific situations.6b,31
Pathway Analysis Based on Oncogene Interactions—Because our study was 
focused on the role of driver oncogenes in the gastric tumor samples that are not always 
measurable by proteomic studies, we combined the proteomics data from the two tumor 
sample sets together with RNA-Seq data for the two ERBB2-expressing gastric cancer cell 
lines SNU16 and KATOIII to construct Table 2. The use of cell lines for measuring the 
transcript data was necessitated by the limited amount of patient samples available precluded 
RNA-Seq analysis. In Supplementary Figure S-3, violin plots are used to summarize via 
histograms the values for RNA-Seq for our selected set of oncogenes obtained from a set of 
58 cases of gastric cancer (TGCA_STAD) and with an overlay of the quantile normalized 
RPKM values for SNU16 and KATOIII as well as other cancer cell lines. Except for 
SKBR(RNA-Seq value for ERBB2 exceeds the range shown in the figure), which is known 
to express very high levels of ERBB2 transcript, the RNA-Seq data for the selected 
oncogenes were consistent with the range observed for the TGCA gastric cancer data set. 
The consistency of the data shown in this plot was supportive of the correlation of the 
proteomic data observed for patient samples with the RNA-Seq data. In addition, ERBB2 
and EGFR, the heterodimeric partner of ERBB2 in ERBB signaling family, were observed 
with significant levels of transcript values in both cell lines (RPKM > 4). For SNU16 other 
selected oncogenes, MYC, ERBB2, GRB7, TP53, TOP2A, and GRB2 were detected with 
RPKM value greater than 10. For KATOIII cell line, MYC, TOP2A, and PPP1R1B have 
RPKM value higher than 10. The value of the transcriptomic information is shown with the 
observation of the high levels of MYC (RPKM values of 141 and 12) in the two cell lines. 
The absence of MYC in proteomic data could be either due to either technology or sample-
related, but as discussed later it was helpful to include MYC in subsequent interaction 
studies. In addition, MYC is a well-documented partner for ERBB2 and EGFR signaling 
pathways.19
Our hypothesis in this study is that ERBB2-driven cancers have a common set of pathways, 
and a more detailed knowledge of individual pathways would aid in the management of this 
disease. Because cancer is a result of complex perturbations between different oncogene-
driven pathways we examined the interaction profile of the tumor specific proteins in the 
ERBB2 expressing cancers.32 Supplementary Table S-4 lists the 51 out of 199 tumor unique 
proteins that have interactions with oncogenes listed in Table 2. In addition, in Figure 6, we 
have mapped the ERBB2 interactions with other expressed oncogenes together with 
transcriptomic and proteomic measurements in the gastric cancer samples. Figure 6 
illustrates ERBB2 and its known interactors (also oncogenes). The oncogenes that have a 
high degree of interaction are drawn closer to ERBB2: EGFR, ERBB3, KRAS, GRB2, 
GRB7, and ERBB2IP. RNA-Seq measurement is denoted by the circle size; for example, 
ERBB and MYC have the largest circle size. Although there are differences between the two 
cell lines, we applied the higher RPKM value in SNU16 or KATOIII to represent cell line 
RNA-Seq value. The oncogenes that have spectral counts equal or higher than have a black 
outline in the figure, for example, ERBB2, EGFR, SRC, GRB2, and GRB7.
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Subpathway Analysis of ERBB2+ versus ERBB2− Sample Sets—On the basis of 
the oncogene list information, for ERBB2+ gastric cancer set, four pathways, namely, ERBB 
family signaling, development EGFR signaling via small GTPases, development EGFR 
signaling, and cytoskeleton remodeling integrin outside-in signaling pathway from the 
GeneGo database,33 were examined for integration of the proteomic and transcriptomic data 
and are listed in Supplementary Figure S-4 (a–d). For purposes of illustration we will 
concentrate on a pathway that fits well with the integration of transcriptomics and 
proteomics data, namely, the ERBB2 signaling pathway from KEGG. (See Figure 7.)34 
Figure 7a shows the correlation between the genes listed in the KEGG pathway and the 
RNA-Seq values for the two gastric cancer cell lines. Transcripts for most of the genes were 
observed, but there are significant exceptions, such as EGF and BTC, AR, and the 
neuregulin genes. Also shown in the Figure are the proteomics identifications (see notation 
of blue stars, whereas the yellow denotes tumor unique proteins). Figure 7b shows a 
simplified version of the ERBB signaling pathway that lists only the subpathways with a 
high number of protein observations and notes identifications, which are increased in 
ERBB2+ versus ERBB2− patient samples. Pathvisio Version 3.2.0 was used to modify the 
pathway to only include genes that have RPKM value higher than 1. The MAPK signaling 
pathway (MEK, ERK) is clearly highlighted in this analysis, which is consistent with 
observation of the importance of this pathway in ERBB2+ gastric cancer and ERBB2+-
driven cancers in general.5d,6b,15,22,32
For comparison, a subpathway associated with ERBB2− gastric cancer is shown in Figure 8, 
namely, actin polymerization and actinmyosin assembly contraction, which is a subpathway 
listed in KEGG as part of the actin cytoskeleton pathway.34 The same analytical process as 
for the ERBB2+ gastric cancer samples was followed with a focus on overexpressed genes 
as measured by transcriptomic and proteomic measurements.32
CONCLUSIONS
In this work, two sets of samples, ERBB2-positive and non-ERBB2 expressing (ERBB2−) 
gastric cancer sample sets were analyzed. FISH experiments for anti-ERBB2 reactivity were 
applied for selection of ERBB2-expressing and non-ERBB2-expressing patient tissue 
samples. Gel loading of extracted protein samples, protein digestion, and LC–MS/MS 
analysis by LTQ-Orbitrap provided in-depth analysis of patient samples. Tumor samples 
were also compared with their adajacent nontumor tissue samples. Two gastrointestinal 
cancer cell lines, SNU16 and KATOIII, were used to provide integration of the RNA-Seq 
data with proteomics data for in-depth analysis of clinical samples. As part of the C-HPP 
initiative, which utilizes proteomics as well as transcriptomics data, oncogene interaction 
values and pathway analysis allowed the identification of pathways and associated 
subpathways with importance in these two subtypes of gastric cancer samples, namely, the 
MAPK signaling pathway and actin polymerization and actinmyosin assembly contraction 
for ERBB2-positive and non-ERBB2-expressing (ERBB2−) gastric cancer sample sets, 
respectively.
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Figure 1. 
Overview of the strategy for analysis of ERBB2-driven gastric cancer. Overview outlines the 
strategy as well as the sample set. A combination of proteomic, transcriptomic, oncogene 
interaction, and pathway analysis was employed in this strategy.
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Figure 2. 
Number of protein observations (N, solid bar) for a given chromosome (listed on X axis) and 
a measure of the number of protein identifications in the study of ERBB2+ gastric cancer 
versus the total number of protein-coding genes for the corresponding chromosome (Protein 
%, red squares on red dotted line; spacing is used to separate highest, lowest, and 
intermediate groups).
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Figure 3. 
CNV detection of Nimblegen human CGH 385 K for gastric cancer patient samples. Copy 
number variation (CNV) for each chromosome for a gastric tumor sample. The highest level 
of variation is in the region of the ERBB2 amplicon on chromosome 17. Test and reference 
cDNA were independently labeled with fluorescent dyes, cohybridized to a NimbleGen 
Human CGH 385 K Whole-Genome Tiling array, and scanned using a 2μm scanner. Log2-
ratio values of the probe signal intensities (Cy3/Cy5) were calculated and plotted versus 
genomic position using Roche NimbleGen NimbleScan software. Data are displayed in 
Roche NimbleGen SignalMap software.
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Figure 4. 
Venn diagram comparing the number of unique protein identifications in ERBB2+ and 
ERBB2− gastric cancer and matching control samples. Figure shows the number of common 
(overlap region) and unique proteins in each sample set.
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Figure 5. 
Identification of genes around ERBB2 genomic region on chromosome 17 in gastric cancer 
and control samples. Red boxes: genes representing the proteins observed only in tumor 
samples of ERBB2+ sample set (not observed in control). Green boxes: genes representing 
the proteins observed in the both tumor and control samples of ERBB2+ sample set. White 
boxes: genes representing the proteins observed with spectral counts less than in all samples. 
MIEN1 is given a white box, as it was observed with only a single spectrum from 
proteomics analysis. Note that while the color of the box denotes the presence of a 
proteomic signal for the gastric cancer samples, the experimental data are given in the box 
below the gene name. Numbers in the top part: spectral counts for tumor, control; bottom 
part: RNA-Seq values for SNU16 and KATOIII respectively. The genomic context of each 
measurement is shown in the circle above the line connecting any two genes. Numbers in the 
left half of the black circle: number of protein-coding genes not observed in the interval 
between each gene observed in our proteomic study and right-hand half is the number of 
genes in this region with RNA-Seq values for SNU16 and KATOIII, respectively. The 
number of bases between the observed genes is given below the connecting line.
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Figure 6. 
Graphic illustration of the process used to prioritize oncogenes of importance for ERBB2+ 
via RNA-Seq, proteomics, and interaction data from GeneCards (www.Genecards.org). The 
following visualization assignments were used: Line length: interaction score (longer line = 
weaker interaction). Circle size: RPKM value (large: RPKM > 15; medium: RPKM between 
and 15; small: RPKM between 1 and 3; RPKM value here is denoted as the higher RPKM 
value in SNU16 or KATOIII for each gene). Black circle: if observed with spectral counts 
equal or higher than from proteomic experiments.
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Figure 7. 
ERBB signaling pathway analysis. (a) Summation of the RNA-Seq and proteomic values for 
genes present in the ERBB signaling pathway from KEGG.34 Red circle: RNA-Seq ≥1 
cutoff value. (The red box means the RPKM value is higher than the cut off. The red color is 
selected only for better clarity. Note this is a different format for visual clarity as the red 
circles provid best contrast with the green boxes used in the KEGG figures.) Blue cross = 
RNA-Seq <1. Blue star = proteomics spectral count value >0. Yellow box = proteomics 
spectral count value >3 only in ERBB2+ tumor sample. (b) Simplified ERBB signaling 
pathway that lists only the subpathways with a high number of protein observations 
(ERBB2+ vs ERBB2− patient samples). All genes illustrated have RPKM value >1, green 
box: spectral counts ≥1; the red star: higher spectral counts in ERBB2+ set (also spectral 
counts in tumor is higher than control). Note that color is selected only for visual clarity.
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Figure 8. 
Summation of the proteomic values for the ERBB2− sample set for genes present in the 
regulation of actin cytoskeleton pathway for ERBB2− set from KEGG. The following 
notations were used: Red star: proteomics value >0 in ERBB2− set (red color is only 
selected for better clarity in the figure). Yellow box: proteomics value >3 spectral count only 
in ERBB2− tumor samples. Green boxes: potentially important pathway functions. Note that 
this is a different format for visual clarity as the red circles provide the best contrast with the 
green boxes used in the KEGG figures.
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